Overview

Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Phase:
Phase 3
Details
Lead Sponsor:
Cardiome Pharma
Correvio International Sarl
Collaborator:
Astellas Pharma US, Inc.